Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Elimination of middle-sized uremic solutes with high-flux and high-cut-off membranes: a randomized in vivo study.

Kneis C, Beck W, Boenisch O, Klefisch F, Deppisch R, Zickler D, Schindler R.

Blood Purif. 2013;36(3-4):287-94. doi: 10.1159/000356224. Epub 2013 Dec 20.

PMID:
24496201
2.

Treatment frequency and efficiency in hemodiafiltration.

Beck W, Techert F, Lebsanft H, Haug U, Deppisch R, Ledebo I, Wizemann V.

Blood Purif. 2013;35(1-3):224-9. doi: 10.1159/000348444. Epub 2013 Apr 27.

PMID:
23635838
3.

Bismuth coating of non-tunneled haemodialysis catheters reduces bacterial colonization: a randomized controlled trial.

Schindler R, Heemann U, Haug U, Stoelck B, Karatas A, Pohle C, Deppisch R, Beck W, Hollenbeck M.

Nephrol Dial Transplant. 2010 Aug;25(8):2651-6. doi: 10.1093/ndt/gfq052. Epub 2010 Mar 17.

4.

Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.

Haag-Weber M, Krämer R, Haake R, Islam MS, Prischl F, Haug U, Nabut JL, Deppisch R; behalf of the DIUREST Study Group.

Nephrol Dial Transplant. 2010 Jul;25(7):2288-96. doi: 10.1093/ndt/gfq087. Epub 2010 Mar 1.

PMID:
20197284
5.

The role of polymer surface degradation and barium sulphate release in the pathogenesis of catheter-related infection.

Verbeke F, Haug U, Dhondt A, Beck W, Schnell A, Dietrich R, Deppisch R, Vanholder R.

Nephrol Dial Transplant. 2010 Apr;25(4):1207-13. doi: 10.1093/ndt/gfp638. Epub 2009 Nov 23.

PMID:
19934097
6.

Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure.

Müller-Krebs S, Kihm LP, Zeier B, Gross ML, Deppisch R, Wieslander A, Henle T, Penndorf I, Oh J, Reiser J, Nawroth PP, Zeier M, Schwenger V.

Eur J Clin Invest. 2008 May;38(5):296-305. doi: 10.1111/j.1365-2362.2008.01945.x. Epub 2008 Mar 16.

PMID:
18346151
8.

Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia.

Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, Jankowski V, Argiles A, Anderstam B, Brunet P, Cerini C, Dou L, Deppisch R, Marescau B, Massy Z, Perna A, Raupachova J, Rodriguez M, Stegmayr B, Vanholder R, Hörl WH; European Uremic Toxin Work Group (EUTox).

Nephrol Dial Transplant. 2007 Dec;22(12):3381-90. Epub 2007 Aug 27. Review. No abstract available. Erratum in: Nephrol Dial Transplant. 2008 Feb;23(2):780.

PMID:
17724037
9.

Differential effects of dialysis and ultrafiltrate from individuals with CKD, with or without diabetes, on platelet phosphatidylserine externalization.

Wang Y, Beck W, Deppisch R, Marshall SM, Hoenich NA, Thompson MG.

Am J Physiol Renal Physiol. 2008 Jan;294(1):F220-8. Epub 2007 Aug 1.

10.

Inconsistency of reported uremic toxin concentrations.

Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drüeke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R.

Artif Organs. 2007 Aug;31(8):600-11. Review.

PMID:
17651115
11.

Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors.

Wang Y, Beck W, Deppisch R, Marshall SM, Hoenich NA, Thompson MG.

Am J Physiol Cell Physiol. 2007 Jul;293(1):C328-36.

12.

Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products.

Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, Ritz E, Bierhaus A, Nawroth PP, Zeier M.

J Am Soc Nephrol. 2006 Jan;17(1):199-207. Epub 2005 Nov 30.

13.

An oral load of the early glycation compound lactuloselysine fails to accumulate in the serum of uraemic patients.

Schwenger V, Morath C, Schönfelder K, Klein W, Weigel K, Deppisch R, Henle T, Ritz E, Zeier M.

Nephrol Dial Transplant. 2006 Feb;21(2):383-8. Epub 2005 Oct 4.

PMID:
16204288
14.

Short bacterial DNA fragments: detection in dialysate and induction of cytokines.

Schindler R, Beck W, Deppisch R, Aussieker M, Wilde A, Göhl H, Frei U.

J Am Soc Nephrol. 2004 Dec;15(12):3207-14.

15.

In vitro evidence for immune activating effect of specific AGE structures retained in uremia.

Glorieux G, Helling R, Henle T, Brunet P, Deppisch R, Lameire N, Vanholder R.

Kidney Int. 2004 Nov;66(5):1873-80.

16.

Protein loss in on-line hemofiltration.

Santoro A, Canova C, Mancini E, Deppisch R, Beck W.

Blood Purif. 2004;22(3):261-8. Epub 2004 May 12.

PMID:
15148454
17.

Prolonged catheter survival in intermittent hemodialysis using a less thrombogenic micropatterned polymer modification.

Baumann M, Witzke O, Dietrich R, Haug U, Deppisch R, Lutz J, Philipp T, Heemann U.

ASAIO J. 2003 Nov-Dec;49(6):708-12.

PMID:
14655739
18.

Evolution of synthetic membranes for blood purification: the case of the Polyflux family.

Ronco C, Crepaldi C, Brendolan A, Bragantini L, d'Intini V, Inguaggiato P, Bonello M, Krause B, Deppisch R, Goehl H, Scabardi A.

Nephrol Dial Transplant. 2003 Aug;18 Suppl 7:vii10-20; discussion vii55. Review. No abstract available.

PMID:
12953024
19.

GDPs and AGEs: local and systemic effects in PD patients.

Ledebo I, Wieslander A, Deppisch R.

Contrib Nephrol. 2003;(140):38-46. Review. No abstract available.

PMID:
12800342
20.

Advanced glycation end products in hemodialyzed patients with diabetes mellitus correlate with leptin and leptin/body fat ratio.

Kalousová M, Sulková S, Zima T, Deppisch R, Beck W, Bednárová sV, Fortová M, Tesar V.

Ren Fail. 2003 Mar;25(2):277-86.

PMID:
12739834
21.

Review on uremic toxins: classification, concentration, and interindividual variability.

Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox).

Kidney Int. 2003 May;63(5):1934-43. Review.

23.

Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?

Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E.

Kidney Int. 2003 Jan;63(1):298-305.

24.

3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis.

Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A.

Kidney Int. 2002 Aug;62(2):697-703.

25.

Uremic toxicity: present state of the art.

Vanholder R, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML.

Int J Artif Organs. 2001 Oct;24(10):695-725. Review.

PMID:
11817319
26.

Glucose degradation products in peritoneal dialysis fluids may have both local and systemic effects: a study of residual fluid and mesothelial cells.

Linden T, Musi B, Järkelid L, Forsbäck G, Kjellstrand P, Deppisch R, Wieslander A.

Perit Dial Int. 2001 Nov-Dec;21(6):607-10.

PMID:
11783771
27.

The un-physiology of peritoneal dialysis solution and the peritoneal membrane: from basic research to clinical nephrology.

La Greca G, Amore A, Armato U, Coles G, Esposito C, Deppisch R, Feriani M, Mason R, Noonan D, Schleicher E, Sterzel B, Gambaro G.

Nephrol Dial Transplant. 2001 May;16(5):905-12. No abstract available.

PMID:
11328894
28.

Biological significance of reducing glucose degradation products in peritoneal dialysis fluids.

Wieslander A, Linden T, Musi B, Carlsson O, Deppisch R.

Perit Dial Int. 2000;20 Suppl 5:S23-7.

PMID:
11229608
29.

Hepatotoxic substance(s) removed by high-flux membranes enhances the positive acute phase response.

Riegel W, Ulrich C, Sauernheimer S, Deppisch RM, Köhler H.

Kidney Int Suppl. 2001 Feb;78:S308-14.

30.

Complement components as uremic toxins and their potential role as mediators of microinflammation.

Deppisch RM, Beck W, Goehl H, Ritz E.

Kidney Int Suppl. 2001 Feb;78:S271-7. Review.

31.

Expression of beta2-microglobulin and c-fos mRNA: is there an influence of high- or low-flux dialyzer membranes?

Haufe CC, Eismann U, Deppisch RM, Stein G.

Kidney Int Suppl. 2001 Feb;78:S177-81.

PMID:
11169006
32.

Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes.

Schröder M, Riedel E, Beck W, Deppisch RM, Pommer W.

Kidney Int Suppl. 2001 Feb;78:S19-24.

33.

Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids.

Wieslander A, Linden T, Musi B, Järkelid L, Speidel R, Beck W, Henle T, Deppisch R.

Contrib Nephrol. 2001;(131):82-9. Review. No abstract available.

PMID:
11125566
34.

One-year immunological evaluation of chronic hemodialysis in end-stage renal disease patients.

Meier P, von Fliedner V, Markert M, van Melle G, Deppisch R, Wauters JP.

Blood Purif. 2000;18(2):128-37.

PMID:
10838472
35.

In vitro cytotoxicity of four different buffers for use in peritoneal dialysis.

Järkelid LE, Svensson E, Deppisch R, Wieslander A.

Altern Lab Anim. 2000 May-Jun;28(3):415-25.

PMID:
25419918
36.

Immunophenotyping and LDL receptor activity analysis in monocytes/macrophages during low- and high-flux haemodialysis.

Forster PB, Deppisch R, Fürst P, Schneider H.

Nephrol Dial Transplant. 1999;14 Suppl 4:49-51. No abstract available.

PMID:
10463217
37.

Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds.

Henle T, Deppisch R, Beck W, Hergesell O, Hänsch GM, Ritz E.

Nephrol Dial Transplant. 1999 Aug;14(8):1968-75.

PMID:
10462279
38.

3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis.

Linden T, Forsbäck G, Deppisch R, Henle T, Wieslander A.

Perit Dial Int. 1998 May-Jun;18(3):290-3.

PMID:
9663893
39.

Microdomain structure of polymeric surfaces--potential for improving blood treatment procedures.

Deppisch R, Göhl H, Smeby L.

Nephrol Dial Transplant. 1998 Jun;13(6):1354-9. Review. No abstract available.

PMID:
9641158
40.

Impact of membrane choice and blood flow pattern on coagulation and heparin requirement--potential consequences on lipid concentrations.

Sperschneider H, Deppisch R, Beck W, Wolf H, Stein G.

Nephrol Dial Transplant. 1997 Dec;12(12):2638-46.

PMID:
9430865
41.

Activation of human neutrophils after contact with cellulose-based haemodialysis membranes: intracellular calcium signalling in single cells.

Hänsch GM, Karnaoukhova S, Chang SH, Rus H, Nicolescu F, Deppisch R, Meissner C, Ludwig H, Ritz E.

Nephrol Dial Transplant. 1996 Dec;11(12):2453-60.

PMID:
9017622
42.

Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis.

Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D.

Intensive Care Med. 1996 Dec;22(12):1360-7.

PMID:
8986487
43.

The Maillard reaction--from food chemistry to uraemia research.

Henle T, Deppisch R, Ritz E.

Nephrol Dial Transplant. 1996 Sep;11(9):1718-22. Review. No abstract available.

PMID:
8918609
44.

Significant reduction of factor D and immunosuppressive complement fragment Ba by hemofiltration.

Kaiser JP, Oppermann M, Götze O, Deppisch R, Göhl H, Asmus G, Röhrich B, von Herrath D, Schaefer K.

Blood Purif. 1995 Nov-Dec;13(6):314-21.

PMID:
8821195
45.

Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances.

Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D.

Kidney Int. 1995 Nov;48(5):1563-70.

46.

L-fucose residues on cellulose-based dialysis membranes: quantification of membrane-associated L-fucose and analysis of specific lectin binding.

Meissner C, Deppisch R, Hug F, Schulze M, Ritz E, Ludwig H, Hänsch G.

Glycoconj J. 1995 Oct;12(5):632-8.

PMID:
8595253
47.

Effect of continuous hemodiafiltration on IL-6, TNF-alpha, C3a, and TCC in patients with SIRS/septic shock using two different membranes.

Braun N, Rosenfeld S, Giolai M, Banzhaf W, Fretschner R, Warth H, Weinstock C, Deppisch R, Erley CM, Müller GA, et al.

Contrib Nephrol. 1995;116:89-98. No abstract available.

PMID:
8529388
48.

Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances.

Hoffmann JN, Faist E, Deppisch R, Hartl WH, Inthorn D.

Contrib Nephrol. 1995;116:76-9. No abstract available.

PMID:
8529385
49.

In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis.

Wieslander AP, Deppisch R, Svensson E, Forsbäck G, Speidel R, Rippe B.

Perit Dial Int. 1995;15(2):158-64.

PMID:
7612737
50.

Immunological determination of advanced glycosylation end-products in human blood and urine.

Dolhofer-Bliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD.

Nephrol Dial Transplant. 1995;10(5):657-64.

PMID:
7566579

Supplemental Content

Loading ...
Support Center